- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03938259
Effect of Opioids on Ventilation in Children With Obstructive Sleep Apnea
March 10, 2021 updated by: Adam Adler MD, MS, FAAP, Baylor College of Medicine
The sole objective in this study is to evaluate if routine amounts of opioids given for tonsillectomy in children have greater amounts of respiratory depression in children with documented obstructive sleep apnea when compared with patients that do not have obstructive sleep apnea
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Ventilatory suppression in children following opioid administration is of obvious concern, especially following routine surgical procedures (i.e.
adenotonsillectomy).
It is thought that patients with obstructive sleep apnea (OSA) have increased sensitivity to opioids, and especially in opioid naïve patients.
Recent evidence in adults suggests that patients with moderate to severe OSA may not predispose patients to increased opioid sensitivity in the form of respiratory depression when compared with patients that do not have OSA.
It is well known that OSA in children is significantly different from OSA in adults (e.g.
gender predilection, central vs. peripheral causation).
The manifestation and etiologies are very different in pediatric OSA making it a vastly different disease process.
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Childrens Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 8 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
We are assessing the effect of fentanyl on children with and without OSA based on the OSA 18 questionnaire and PSG resepctively.
Children must be otherwise healthy as stated above in the eligibility criteria
Description
Inclusion Criteria:
- tonsillectomy or adenotonsillectomy
- Ages 2 to 8 years
- Polysomnography with AHI >6 (study group)
- Polysomnography with AHI =0 or negative OSA 18 questionnaire (control group)
Exclusion Criteria:
- Ages >8 years
- Patients requiring pre-medication
- Parental refusal
- Opioid allergy/intolerance
- Patients requiring propofol for intubation
- Patients with known or suspected difficult airway
- Obesity with body mass index exceeding 30- (control group only)
- Known cardiovascular disorders
- Known pulmonary disorders aside from asthma
- Patients with chronic oxygen requirement
- History of Prematurity <35 weeks of gestation
- No recent URI
- Personal of family history of malignant hyperthermia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Control group; patients without obstructive sleep apnea
Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
|
identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
Other Names:
|
Patients with known obstructive sleep apnea
Children with OSA having adenotonsillectomy for obstructive apnea will receive opioids with evaluation of respiratory changes
|
identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory depression following opioids
Time Frame: respiratory rate measured 10 minutes following opioid administration
|
Identification of respiratory depression following fentanyl administration by recording the respiratory rate prior to and 10 minutes following fentanyl administration
|
respiratory rate measured 10 minutes following opioid administration
|
Respiratory depression following opioids
Time Frame: tidal volume measured 10 minutes following opioid administration
|
Identification of respiratory depression following fentanyl administration by recording the tidal volume prior to and 10 minutes following fentanyl administration Identification of respiratory depression following fentanyl administration by recording the tidal volume prior to and 10 minutes following fentanyl administration
|
tidal volume measured 10 minutes following opioid administration
|
Respiratory depression following opioids
Time Frame: end tidal co2 measured 10 minutes following opioid administration
|
Identification of respiratory depression following fentanyl administration by recording the end-tidal co2 prior to and 10 minutes following fentanyl administration
|
end tidal co2 measured 10 minutes following opioid administration
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory depression following opioids
Time Frame: measured 10 minutes following opioid administration
|
identification of ethnicity as a factor related to opioid induced respiratory depression
|
measured 10 minutes following opioid administration
|
Respiratory depression following opioids
Time Frame: measured 10 minutes following opioid administration
|
identification of preoperative SpO2 nadir (> or < 85%) as a factor related to opioid induced respiratory depression
|
measured 10 minutes following opioid administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 1, 2019
Primary Completion (ACTUAL)
August 30, 2020
Study Completion (ACTUAL)
August 30, 2020
Study Registration Dates
First Submitted
April 27, 2019
First Submitted That Met QC Criteria
May 2, 2019
First Posted (ACTUAL)
May 6, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 12, 2021
Last Update Submitted That Met QC Criteria
March 10, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Signs and Symptoms, Respiratory
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Respiratory Insufficiency
- Apnea
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Fentanyl
Other Study ID Numbers
- H-45486
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No information about IP will be shared per the IRB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
ApnimedCompletedOSA - Obstructive Sleep ApneaUnited States
-
ResMedCompletedObstructive Sleep Apnea (OSA)United States, Australia
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
Clinical Trials on Fentanyl
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)CompletedPeer Review, ResearchUnited States
-
Alexza Pharmaceuticals, Inc.Completed
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
University of Texas Southwestern Medical CenterCompletedPregnancyUnited States
-
Samuel Lunenfeld Research Institute, Mount Sinai...Terminated
-
Janssen Research & Development, LLCCompleted
-
University of PatrasUnknownStillborn Caesarean SectionGreece
-
Johns Hopkins UniversityCompletedIntracranial SurgeryUnited States
-
Janssen Korea, Ltd., KoreaCompletedChronic PainKorea, Republic of